Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Samsung BioLogics
Pharma
Astellas, Otsuka, Samsung Biologics—Fierce Pharma Asia
Astellas' CLDN18.2 drug cleared the FDA. Otsuka reported positive readout in IgAN. Samsung Bio signed its largest contract to date. Plus more.
Angus Liu
Oct 25, 2024 8:43am
Samsung Biologics bags $1.2B production contract
Oct 22, 2024 10:02am
Headhunter lays out leadership goals for CDMO industry
Aug 14, 2024 10:51am
China deals, Enhertu, Samsung Bio—Fierce Pharma Asia
Jul 26, 2024 1:45am
Samsung Biologics' 37% sales surge propelled by biosimilars
Jul 24, 2024 10:56am
Eisai, Takeda, BIOSECURE—Fierce Pharma Asia
Jul 12, 2024 9:05am